Loftyrock Investment

Loftyrock Investment is a Seoul-based venture capital firm founded in 2021, funding biotechnology and other technology-driven sectors and focusing on opportunities created by technological breakthroughs and convergence.

Dohyung Kim Ph.D

CEO

2 past transactions

Genedit

Series A in 2024
GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

Galux

Series A in 2022
Galux specializes in molecular design technology for discovering and developing novel drugs targeting incurable and rare diseases. Its AI-based platform integrates artificial intelligence, physics, and chemistry to design biomolecules, aiding healthcare professionals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.